Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
CAMBRIDGE, Mass., Feb. 02, 2016 -- Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of common stock from Editas Medicine at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The company’s common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading on Wednesday, February 3, 2016 under the ticker symbol “EDIT.”
Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager, and JMP Securities is acting as co-manager for the offering.
A registration statement relating to the securities being sold in this offering has been filed with and declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
[email protected]
Investor Contact
Jesse Baumgartner
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
